TRACERx

一行要約

切除可能 NSCLC を対象とした前向きコホート研究。多領域全エクソームシークエンシングと ctDNA 縦断追跡により 腫瘍内不均一性 (ITH)・サブクローン進化・ctDNA-MRD の基盤概念を確立した、肺癌ゲノミクスの landmark study。

試験デザイン

• 対象: Stage I-III の手術予定 NSCLC、UK 13 施設、目標登録 N=842
• デザイン: 前向き縦断コホート (治療介入なし)。手術時に多領域 (≥2 regions) 腫瘍検体を採取し、matched blood による多領域全エクソームシークエンシング (WES) を実施
• 追跡: 術後 ctDNA を定期採取。再発時に可能であれば再生検
• 目的: (1) clonal vs subclonal mutation の landscape、(2) clonal evolution under selective pressure、(3) ctDNA-based MRD 検出と再発予測

主要結果

• 腫瘍内不均一性 (ITH) : NSCLC の mutation burden の中央値 約30% がサブクローナル。EGFR / KRAS 等の driver mutation はほぼ全例 clonal (trunk mutation)
• Chromosomal instability (CIN) : 高 CIN は ITH 増加・再発リスク上昇と相関。APOBEC 変異シグネチャーがサブクローン進化の主要ドライバー
• ctDNA-MRD (Nature 2023) : 術後 ctDNA 検出は再発を median 200 日以上先行して予測。ctDNA 検出感度はステージ・腫瘍量に依存
• Clonal neoantigen と免疫逃避: Clonal neoantigen burden が高い腫瘍は免疫応答が強く、HLA LOH / neoantigen editing による免疫逃避が進化の選択圧
• 再発時のクローン構造: 再発腫瘍はしばしば minor subclone から派生し、adjuvant therapy が selective bottleneck として機能

臨床的意義

• ctDNA-MRD の clinical utility: TRACERx の知見が adjuvant therapy の escalation/de-escalation 戦略 (MRD-guided adjuvant) の理論的根拠
• 腫瘍不均一性と薬剤耐性: 治療前から存在する resistant subclone が progression の seed となる概念を実証。Lineage-plasticity や EMT との関連
• 免疫療法の biomarker: Clonal neoantigen burden が PD-1 inhibitor 効果と相関する仮説の基盤 (TRACERx → CheckMate-227 等での TMB 解析へ)
• Liquid biopsy の foundation: ctDNA tracking by phylogenetic-informed assay の概念を確立

Open Questions

• MRD-guided adjuvant の prospective validation: ctDNA 陽性/陰性で adjuvant IO を escalate/de-escalate する RCT は進行中 (MERMAID 等)
• Subclonal driver の治療標的化: 主要 driver は clonal だが、resistance clone の subclonal driver を先制標的とする戦略
• TRACERx 知見の他癌種への一般化: TRACERx Renal / TRACERx Melanoma との比較
• APOBEC mutagenesis の制御可能性: サブクローン進化を抑制する新規治療コンセプト

重要論文 Top 10

1. ★★★★★ Jamal-Hanjani et al. NEnglJMed 2017 — TRACERx 100 — 初回 report、ITH landscape
2. ★★★★★ Abbosh et al. Nature 2017 — TRACERx ctDNA — 術後 MRD の phylogenetic tracking
3. ★★★★★ Abbosh et al. Nature 2023 — TRACERx 421 — ctDNA-MRD 大規模 validation
4. McGranahan et al. — Clonal neoantigen burden と immune checkpoint response
5. ★★★★ Swanton et al. Cell 2024 — TRACERx 最終解析まとめ — 842 例の evolutionary atlas

関連エンティティ・概念

• EGFR / KRAS / TP53 — Trunk driver mutations
• Lineage-plasticity — サブクローン進化と表現型転換
• EMT — 進化過程での plasticity
• PD-L1 — Clonal neoantigen と IO 応答
• ADAURA — MRD-guided adjuvant の応用文脈

関連論文

直近 30 件のみ表示中 (関連 38 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Extracellular vesicles

• Swanton et al. Cell 2024 — Embracing cancer complexity Hallmarks of systemic disease

Basic-Immunotherapy

• Montesion et al. CancerDiscov 2021 — Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden
• McGranahan et al. Cell 2017 — Allele-specific HLA loss and immune escape in lung cancer evolution
• Rosenthal et al. Nature 2019 — Neoantigen-directed immune escape in lung cancer evolution

Basic-Liquid-biopsy

• Gale et al. AnnOncol 2022 — Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
• Kilgour et al. CancerCell 2020 — Liquid biopsy-based biomarkers of treatment response and resistance
• Black et al. Cell 2025 — Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction
• Blackhall et al. LancetOncol 2018 — Will liquid biopsies improve outcomes for patients with small-cell lung cancer
• Aggarwal et al. NatRevClinOncol 2021 — Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice
• Abbosh et al. Nature 2023 — Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Basic-Neutrophil and myeloid cell

• Enfield et al. CancerDiscov 2024 — Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer

Basic-Oncogene and genetics

• McGranahan et al. Cell 2017 — Clonal heterogeneity and tumor evolution past, present, and the future
• Jamal-Hanjani et al. NEnglJMed 2017 — Tracking the evolution of non-small-cell lung cancer
• Pich et al. NEnglJMed 2025 — Tumor-infiltrating clonal hematopoiesis
• Mina et al. NatGenet 2020 — Discovering functional evolutionary dependencies in human cancers
• Reiter et al. NatRevCancer 2019 — An analysis of genetic heterogeneity in untreated cancers
• Nam et al. NatRevGenet 2021 — Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics
• Watkins et al. Nature 2020 — Pervasive chromosomal instability and karyotype order in tumour evolution
• Hessey et al. Nature 2026 — Evolutionary characterization of lung cancer metastasis
• Pich et al. Nature 2026 — Somatic evolution following cancer treatment in normal tissue

Basic-Others

• Winslow et al. CancerDiscov 2026 — A roadmap to transform lung cancer outcomes priorities in biology, therapeutic innovation, early detection, prevention
• Quail et al. Cell 2026 — Cancer ecosystems a dynamic interplay across scales

Clinical-Epidemiology

• Pandya et al. Cell 2026 — Plasma signals of lung tumor promotion for molecular cancer prevention

Clinical-Methodology

• Liu et al. NatRevCancer 2026 — Advancing AI for multi-omics and clinical data integration in basic and translational cancer research

Clinical-NEC

• Lindsay et al. BrJCancer 2021 — Large cell neuroendocrine lung carcinoma consensus statement from the british thoracic oncology group and the

Clinical-NSCLC-ALK

• Pailler et al. ClinCancerRes 2019 — Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in

Clinical-NSCLC-Driver negative

• Willmann et al. JClinOncol 2026 — Metastatic trajectories in non-small cell lung cancer guide local and systemic therapies
• Fick et al. JThoracCardiovascSurg 2025 — High-risk features associated with recurrence in stage I lung adenocarcinoma

Clinical-NSCLC-Driver-Other

• Luo et al. Med 2026 — Nsclc five trials to watch

Clinical-NSCLC-EGFR

• Kunimasa et al. AnnOncol 2018 — Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1